Convalescent Plasma Therapy for COVID-19 Prophylaxis in Adults Early Post-Hematopoietic Stem Cell Transplantation: One-Year Outcomes from a Randomized Controlled Trial

Cao et al., Frontiers in Immunology, doi:10.3389/fimmu.2025.162677, Nov 2025
ProphylaxisRCT · 72 patients · China · Jun 2023 – Feb 2024
Conv. Plasma for COVID-19
Outcome
Improvement
Relative Risk · 95% CI
Higher mortality with convalescent plasma
p = 0.044
RCT 72 hematopoietic stem cell transplantation (HSCT) recipients, showing higher one-year mortality with COVID-19 convalescent plasma prophylaxis treatment.
Standard of Care (SOC) for COVID-19 in the study country, China, is average with moderate efficacy for approved treatments1.
OutcomeImprovementEffect · pTreatmentControl
risk of death 224.1% higher · RR 3.24 · p = 0.04* 224.1% higherRR 3.24p = 0.04* 36 36 treatment 36, control 36day 365
risk of severe case 0.0% lower · RR 1.00 · p = 1.00 0.0% lowerRR 1.00p = 1.00 1 of 36 (2.8%) 1 of 36 (2.8%) treatment 1 of 36 (2.8%), control 1 of 36 (2.8%)day 120
risk of case 40.2% higher · RR 1.40 · p = 0.46 40.2% higherRR 1.40p = 0.46 36 36 treatment 36, control 36day 120

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. * p < 0.05

Cao et al., 11 Nov 2025, Randomized Controlled Trial, China, peer-reviewed, 22 authors, study period June 2023 - February 2024. Contact: sunjiali@ihcams.ac.cn, doctor_eljiang@163.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 China Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Benin Burundi Cameroon CAR China favored low-cost treatments.The average efficacy of treatments was moderate.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 China Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Benin Burundi CAR Syria China favored low-cost treatments.The average efficacy was moderate.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%